The biochip enables accurate detection of the specific virus or bacteria within one minute. Credit: Opteev Technologies/PRNewswire.

Opteev Technologies has announced the filing of a patent for a new multiplex biochip that can precisely identify Flu, SARS-CoV-2, RSV and respiratory pathogens.

The new polymer-based biochip is intended for testing multiple pathogens that can cause these respiratory infections.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Designed to accurately detect the specific virus or bacteria within one minute, the new technology is expected to provide a path for a new precise, ultra-rapid, portable and syndromic diagnostic device to offer healthcare providers immediate access to results.

Opteev Technologies virology and diagnostics vice-president Dr Mesfin Meshesha said: “With the development of our multiplex biochip, we are revolutionising point-of-care diagnostics.

“The potential of this technology to transform patient care, streamline operations and reduce costs is truly remarkable.”

The tiny biochip can instantly identify complete viruses in real-time in unprocessed and processed samples such as nasal swabs or saliva.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It has exhibited an accuracy rate of 99.49% with a notable limit of detection in the analytical performance assessment.

The biosensor attains specificity by choosing specific virus-binding peptides, thereby facilitating accurate target virus detection in complex samples.

The biochip leverages artificial intelligence to optimise the frequency range, effectively addressing the impact of interfering noise signals and ensuring precise virus detection.

Opteev chairman and co-founder Conrad Bessemer said: “Together, we can shape the future of diagnostics and unlock the massive potential of our game-changing multiplex biochip.”

Novatec subsidiary Opteev focuses on the development of solutions for point-of-care diagnostics.